In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Ixabepilone(BMS-247550), an epothilone B analog, is an orally bioavailable microtubule inhibitor . It could bind to tubulin and promote tubulin polymerization and microtubule stabilization, thereby arresting cells in the G2-M phase of the cell cycle and inducing tumor cell apoptosis.
In vitro: In a large panel of tumor cell lines, BMS-247550 was as active as epothilone B in inducing cytotoxicity. Of the 21 cells lines tested, the IC50 values were in the range of 1.4–34.5 nm. BMS-247550 almost completely blocked cells in mitosis as early as 8 h after the initiation of drug exposureat a concentration close to the IC90 (7.5 nm, clonogenic cytotoxicity assay) .
In vivo: BMS-247550 has clearly demonstrated antitumor activity that is superior to paclitaxel in both paclitaxel-sensitive and -resistant tumors. BMS-247550 was more efficacious than paclitaxel in all five paclitaxel-resistant tumors such as the clinically derived paclitaxel resistant Pat-7 ovarian carcinoma, the A2780Tax ovarian carcinoma that is resistant to paclitaxel because of tubulin mutations, the HCT116/VM46 MDR colon carcinoma, the clinically derived paclitaxel-resistant Pat-21 breast carcinoma, and the murine fibrosarcoma M5076. BMS-247550 produced antitumor activity equivalent to paclitaxel against three paclitaxel-sensitive human tumor xenografts such as A2780 human ovarian carcinoma, HCT116, and LS174T human colon carcinoma .
Clinical trials:Numerous phase I trials have evaluated the optimum dose and toxicity associated with ixabepilone. Various phase II studies were designed for patients with varying levels of previous therapies based on ample evidence of response and safety in early trials such as patients with taxane-refractory breast cancer, taxane-naive patients, both taxane-naive and taxane-refractory patients, taxane refractory patients.
. Lee FY1, Borzilleri R,Fairchild CR, Kim SH, Long BH, Reventos-Suarez C, Vite GD, Rose WC, Kramer RA.BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res.2001 May;7(5):1429-37
. Denduluri N, Low J A, Lee J J, et al. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes[J]. Journal of clinical oncology, 2007, 25(23): 3421-3427.
. Shannon Puhalla, Adam Brufsky. Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancer. Biologics. 2008 Sep; 2(3): 505–515.
|Physical Appearance||A solid|
|Storage||Store at -20°C|
|Synonyms||Azaepothilone B; BMS 247550; BMS 247550-1; Ixempra|
|Solubility||≥22.25 mg/mL in DMSO, ≥41.3 mg/mL in EtOH with gentle warming, <2.14 mg/mL in H2O|